Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Kristinsson, Sigurdur Yngvi
Andersson, Therese M-L
Derolf, Asa Rangert
Dickman, Paul W
MetadataShow full item record
CitationJ. Clin. Oncol. 2012, 30(24):2995-3001
AbstractReported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life expectancy, whereas patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately reduced survival in most, but not all, studies. We conducted a large population-based study to establish patterns of survival in more than 9,000 patients with MPNs. We identified 9,384 patients with MPNs (from the Swedish Cancer Register) diagnosed from 1973 to 2008 (divided into four calendar periods) with follow-up to 2009. Relative survival ratios (RSRs) and excess mortality rate ratios were computed as measures of survival. Patient survival was considerably lower in all MPN subtypes compared with expected survival in the general population, reflected in 10-year RSRs of 0.64 (95% CI, 0.62 to 0.67) in patients with PV, 0.68 (95% CI, 0.64 to 0.71) in those with ET, and 0.21 (95% CI, 0.18 to 0.25) in those with PMF. Excess mortality was observed in patients with any MPN subtype during all four calendar periods (P < .001). Survival improved significantly over time (P < .001); however, the improvement was less pronounced after the year 2000 and was confined to patients with PV and ET. We found patients with any MPN subtype to have significantly reduced life expectancy compared with the general population. The improvement over time is most likely explained by better overall clinical management of patients with MPN. The decreased life expectancy even in the most recent calendar period emphasizes the need for new treatment options for these patients.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
- Authors: Price GL, Davis KL, Karve S, Pohl G, Walgren RA
- Issue date: 2014
- Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
- Authors: Roaldsnes C, Holst R, Frederiksen H, Ghanima W
- Issue date: 2017 Jan
- Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
- Authors: Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M
- Issue date: 2008 Sep 15
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
- Authors: Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf ÅR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC, Björkholm M
- Issue date: 2015 Jul 10
- Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.
- Authors: Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M
- Issue date: 2007 May 20